Symphogen A/S
http://www.symphogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Symphogen A/S
Sumitomo Pharma To Cut 400 US Employees Amid Latuda LOE
After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Global crises and a tough funding environment mean biopharma leadership teams need to work hard to survive, let alone thrive. Industry executives shared their predictions and advice on strategy for 2024.
What Verona Needs To Make COPD Drug Ensifentrine A Success
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
Finance Watch: Turnstone Biologics Launches 14th Biopharma IPO Of 2023
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Receptor BioLogix, Inc.
- Symphogen Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice